AMSTERDAM and BARCELONA, Spain, September 9, 2016 /PRNewswire/ --
- Optimized to support minimally
invasive treatment of liver cancer - the second most
deadly cancer, accounting for 745,000 annual deaths
worldwide[1]
- Features world's first optimized
imaging for radiopaque beads (LC Bead
LUMITM)** for tumor
treatment, minimizing damage to surrounding
healthy tissue and organs
- OncoSuite enables a unique complete coverage
of the liver to visualize peripheral hepatic
tumors
Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it
will unveil its latest innovation in interventional oncology at the
2016 Cardiovascular and Interventional Radiological Society of
Europe annual meeting (CIRSE
2016), which will be held in Barcelona (Spain) from September
10 until 14. Philips' next generation interventional
oncology solution OncoSuite will enable physicians to provide
analysis and minimally invasive, targeted treatment of tumor
lesions reducing the impact to healthy tissue. It offers clinicians
a better view of the treatment targets for informed decision
making, while performing the procedure.
(Photo:
http://photos.prnewswire.com/prnh/20160908/405684 )
(Photo:
http://photos.prnewswire.com/prnh/20160908/405685 )
"While OncoSuite can be used for a number of different cancers
including bone, kidney and lung, the solution and its specific
tools have been optimized for the treatment of patients with liver
cancer," said Dr Jeff Geschwind,
Chairman and Chief of the Department of Radiology and Biomedical
Imaging at the Yale School of Medicine.
"Given the steady increase in the prevalence of non-alcoholic fatty
liver disease and liver cancer,
[2] the development and
availability of new technology is much needed to provide
interventional oncologists with a breakthrough that allows best
possible treatment for these patients."
Dr. Geschwind continued: "What matters most in these cases, is
the ability to visualize the liver tumors, even small ones, during
the procedure and to approach them in a very targeted way to
maximize the therapeutic outcome, while avoiding the destruction of
healthy liver tissue. OncoSuite is designed to help us see, reach
and treat liver cancer in a better
way."[3]-[5]
OncoSuite is Philips' integrated solution to enhance tumor
embolization and ablation procedures with Philips' interventional
X-ray systems. It is the only platform in the industry that
supports both procedures enabling physicians to target multiple
tumor lesions simultaneously. OncoSuite comprises Philips'
innovative product offerings for enhanced imaging (XperCT Dual),
live 3D image guidance for tumor embolization (EmboGuide) and live
3D image guidance for tumor ablation (XperGuide). It is yet another
example of Philips' Image Guided Therapy solutions that advances
minimally invasive procedures by helping physicians decide, guide,
treat and confirm the right therapy for each patient.
"Minimally invasive, image-guided interventional oncology
procedures are a highly effective option for patients who cannot be
treated through conventional techniques such as surgery,
chemotherapy or radiation therapy," said Ronald Tabaksblat,
Business Leader Image Guided Therapy Systems at Philips.
"Interventional oncology procedures are rapidly increasing and
OncoSuite provides the first complete interventional oncology
portfolio for interventional radiologists, enabling physicians to
see the entire tumor and its feeder vessels to directly target
treatment avoiding healthy tissue."
The next generation OncoSuite allows targeted treatment of an
entire tumor and its feeder vessels, sparing surrounding tissue or
organs. The innovative Open Trajectory function within
XperCT Dual enables better centering of the liver with
significantly improved visualization during the procedure of
peripheral hepatic tumors in a single
sweep.[6] This feature provides a
more targeted field of view making it possible to effectively scan
larger patients. Previously, with the traditional geometric
movement of the C-arm of the interventional X-ray system, part of
the liver image was truncated and larger patients required multiple
scans to visualize tumors in the periphery of the liver.
Embolization procedures involve blocking the arteries feeding a
tumor with beads to deprive it of nutrients and oxygen. They
require the insertion of a catheter, which must be guided to the
tumor site with the aid of live image-guidance. BTG and Philips
have been working in close collaboration on the visualization
benefits of radio-opaque beads in combination with image-guided
therapy. Together the companies have calibrated LC Bead
LUMITMand Philips Live Image Guidance Software to help
interventional radiologists and multi-disciplinary teams to
visualize better treatment options for patients with liver cancer.
As a result, the next generation OncoSuite also features the
world's first optimized imaging for LC Bead LUMITM that
provides real-time visible confirmation of bead location during
embolization procedures.[7] In
addition, the new Wiper Movement functionality improves workflow
with automatic Dual Phase imaging, helping physicians to acquire
two 3D cone beam CT datasets at different times of the procedure in
a single step.
The next generation OncoSuite reflects Philips' commitment to
deliver better, more personalized care to patients, while reducing
healthcare costs. For more information on Philips presence at the
CIRSE Congress 2016, please visit here and follow the #CIRSE2016
conversation @PhilipsLiveFrom throughout the event. OncoSuite and
Philips' full suite of integrated radiology solutions will also be
featured at the upcoming 2016 RSNA annual meeting in Chicago (US) later this year. For continuous
updates on Philips' presence at RSNA 2016, please visit here.
References and notes:
* OncoSuite is the combination of
Philips' innovative product offerings XperCT Dual,
EmboGuide and XperGuide. XperCT Dual rel3.3 with Open
Trajectory and XperCT for LUMI optimized imaging is
not yet CE marked, and not yet available for
delivery.
** LC Bead
LUMITM is the official trademark of BTG
(Biocompatibles UK Ltd.) and is not available as part of
Philips' OncoSuite.
[1] Stewart, BW, Wild CW. World
Cancer Report. 2014. Available at:
https://shop.iarc.fr/products/wcr2014 Accessed August 2016
[2] Tucker, ME. Fatty Liver
Disease Surging as Liver Cancer Cause. 2015. Available at:
http://www.medscape.com/viewarticle/843733 Accessed August 2016
[3] Loffroy R, et al.
Intraprocedural C-arm dual-phase cone-beam CT: can it be used to
predict short-term response to TACE with drug-eluting beads in
patients with hepatocellular carcinoma? Radiol. 2013
Feb;266(2):636-48
[4] Miyayama S, et al.
Efficacy of automated tumor-feeder detection software using
cone-beam computed tomography technology in transarterial
embolization through extrahepatic collateral vessels for malignant
hepatic tumors. Hepatol Res. 2016 Feb;46(2):166-73
[5] Schernthaner RE, et al.
Improved Visibility of Metastatic Disease in the Liver During
Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT.
Cardiovasc Intervent Radiol. 2016 Jul
5. [Epub ahead of print]
[6] Schernthaner RE, et al.
Feasibility of a modified cone-beam CT rotation trajectory to
improve liver periphery visualization during transarterial
chemoembolization. Radiology.
2015;277(3):833-41
[7] Levy EB, et al. First Human
Experience with Directly Image-able Iodinated Embolization
Microbeads. Cardiovasc Intervent Radiol. 2016
Aug;39(8):1177-86
This material is not meant for distribution in the USA.
About Royal
Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a leading health technology company focused on improving
people's health and enabling better outcomes across the health
continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' health
technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000
employees with sales and services in more than 100 countries. News
about Philips can be found
at http://www.philips.com/newscenter.
For further information, please contact:
Steve Klink
Philips Group Communications
Tel.: +31-6-10888824
E-mail: steve.klink@philips.com
Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31-6-22698001
E-mail: fabienne.van.der.feer@philips.com